<DOC>
	<DOCNO>NCT02732899</DOCNO>
	<brief_summary>To determine safety efficacy intravitreal injection Sirolimus adjunct EYLEA subject exudative age relate macular degeneration ( AMD ) persistent intraretinal subretinal edema due neovascular AMD despite previous intravitreal antiVEGF treatment .</brief_summary>
	<brief_title>Sirolimus Conjunction With Eylea v Eylea Alone Exudative AMD</brief_title>
	<detailed_description>This study single-center , mask , randomize , 36 week study , design evaluate safety treatment efficacy intravitreal Sirolimus adjunct EYLEA® ( aflibercept ) patient persistent edema due neovascular AMD versus EYLEA® ( aflibercept ) alone . Twenty ( 20 ) patient randomize receive study medication 1:1 ratio . Study treatment administer intravitreal injection . The sham injection give EYLEA® alone group needleless give order help preserve masking subject treatment group .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Male female patient , 50 year age old baseline 2 . Patient completed/signed informed consent prior studyrelated procedure able follow study instruction likely complete require visit . • Ocular Inclusion Criteria ( Study eye ) : 3 . BCVA 5 75 ( 20/80020/30 ) , inclusive , study eye ; eye eligible , eye best potential visual improvement determine investigator select treatment . 4 . Presence choroidal neovascularization secondary AMD 5 . At least 3 previous intravitreal antiVEGF injection past 6 month 6 . Injection AntiVEGF may defer least 4 week randomization base clinical assessment AMD investigator . 7 . Clear ocular medium adequate pupil dilation permit good quality photographic image 1 . Females pregnant , nursing , plan pregnancy childbearing potential use reliable method contraception . 2 . History current evidence hypersensitivity component study medication fluorescein , assess investigator . 3 . Participation investigational drug device study within 30 day prior baseline 4 . History current evidence medical condition may , opinion investigator , preclude safe administration study medication affect result study . • Ocular Exclusion Criteria ( Study eye ) : 5 . Decrease great 150 micron central subfield thickness measure OCT since last intravitreal injection study eye 6 . Aphakia 7 . History par plana vitrectomy study eye 8 . History major ophthalmic surgery study eye past 3 month ophthalmic surgery study eye within past 30 day 9 . History significant ocular disease condition exudative AMD may confound result 10 . Uncontrolled glaucoma ( defined intraocular pressure &gt; 21mm Hg despite treatment two ocular hypotensive medication baseline ) 11 . No active ocular periocular infection , ocular malignancy include lymphoma 12 . Presence significant epiretinal membrane 13 . Significant vitreoretinal traction</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>AMD</keyword>
</DOC>